Skip to content

Quick ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
5.1×-0.7×
AbbVie logo
AbbVieABBV
0.7×0.0×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

Based on the most recent quarter.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s quick ratio?
SELLAS Life Sciences Group, Inc. (SLS) reported quick ratio of 17.2× in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s quick ratio changed year-over-year?
SELLAS Life Sciences Group, Inc.'s quick ratio increased by 271.0% year-over-year, from 4.6× to 17.2×.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s quick ratio?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s quick ratio has grown at a 29.1% compound annual growth rate (CAGR), from 3× to 10.7×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.